V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC History: From GHRH to Albumin Conjugate
CJC-1295 DACHistory

CJC-1295 DAC History: From GHRH to Albumin Conjugate

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How did CJC-1295 with DAC come to exist? The line runs from the 1982 isolation of human GHRH from pancreatic tumors, through the finding that the first 29 residues carry the activity, to the discovery that plasma dipeptidyl peptidase IV cleaves the N-terminus and inactivates the hormone within minutes. Stabilizing substitutions produced tetrasubstituted GRF(1-29); adding a maleimide linker that reacts with Cys34 of serum albumin produced the DAC (drug affinity complex) form, described in rats in 2005 and in GHRH-knockout mice in 2006. This article is a sourced timeline for laboratory research. V8 supplies the no-DAC form; this is a history, not a product pitch. For laboratory research use only.

Every compound has a design logic that is easiest to see by following the problems its inventors were trying to solve. For CJC-1295 with DAC the sequence is unusually clear: a hormone is discovered, its active core is identified, a specific enzymatic weakness is found, the weakness is patched chemically and then the patched molecule is given a way to avoid clearance altogether. This article follows that chain with citations and notes where each step still shapes how the molecule is used as a laboratory reagent. It is a history and not a handling guide, and it concerns research materials only; not for human or animal consumption.

Timeline at a glance

YearEventSource
1982GHRH purified and sequenced from human pancreatic tumors associated with acromegaly, independently by two groupsGuillemin et al.; Rivier et al.
1985Transgenic mice expressing human GRF show increased somatic growth, confirming the peptide’s biology in vivoHammer et al.
1986Plasma dipeptidylaminopeptidase found to inactivate GHRH by cleaving the N-terminus, producing GHRH(3-44)Frohman et al.
2005Maleimido GRF(1-29) derivatives conjugated to albumin; CJC-1295 identified as the bestJetté et al.
2006CJC-1295 normalizes growth in GHRH-knockout mice at once-daily intervalsAlba et al.

1982: a hormone with a name and a sequence

The existence of a hypothalamic factor that stimulates growth hormone release had been inferred for decades before it was isolated. In 1982 two laboratories reported the purification of a growth-hormone-releasing factor from human pancreatic islet tumors associated with acromegaly, a condition of growth hormone excess; one group published in Science (Guillemin and colleagues, 1982) and the other in Nature (Rivier and colleagues, 1982). The tumor source mattered because these tumors secrete the factor in quantities that the hypothalamus does not, which made isolation possible. The result was a 44-residue peptide, GHRH(1-44)-amide. Subsequent structure–activity work showed that the N-terminal 29 residues retain activity at the receptor, and that fragment, GHRH(1-29)-amide, became the core of the analog family discussed on the sermorelin research page. A transgenic mouse study in 1985 then showed that sustained expression of human GRF drove increased somatic growth, establishing the peptide’s function in a whole animal (Hammer and colleagues, 1985).

1986: the half-life problem

A natural hormone is a poor reagent if it disappears before it can be studied. Frohman and colleagues (1986) incubated GHRH(1-44)-amide with human plasma and found that, by HPLC, the intact peptide disappeared with a half-life of 17 minutes in vitro, with appearance of a less hydrophobic product that retained immunoreactivity. Sequence analysis identified it as GHRH(3-44)-amide, with biologic activity below one-thousandth that of the parent. In vivo, the HPLC-defined half-life of the intact hormone was 6.8 minutes after intravenous administration in normal subjects, and the authors concluded that a plasma dipeptidylaminopeptidase was inactivating GHRH. This single paper explains much of the later design work: the vulnerable bond is at the N-terminus, so protecting it, for example by replacing alanine at position 2 with a D-amino acid, blocks the enzyme. That substitution is one of the four defining features of the modified GRF(1-29) described on the CJC-1295 (No DAC) research guide.

From protected fragment to albumin conjugate

Stabilizing the peptide against cleavage helps, but it does not stop renal clearance of a 3 kDa peptide. A separate strategy exploits the fact that serum albumin is large, abundant and long-lived. Kratz (2008) reviewed albumin as a drug carrier, covering coupling of drugs to albumin and the covalent or physical binding of peptides to albumin to enhance stability and half-life. Part of the reason that residence is long is that the neonatal Fc receptor (FcRn) binds albumin and protects it from degradation, prolonging its half-life (Chaudhury and colleagues, 2003). The idea behind the "drug affinity complex" is to attach a reactive group so that a peptide binds covalently to albumin after it enters the bloodstream and then shares albumin’s longer lifetime.

In 2005, Jetté and colleagues described three maleimido derivatives of hGRF(1-29) bioconjugated to human serum albumin. All three showed enhanced in vitro stability against dipeptidylpeptidase IV and were bioactive in cultured rat anterior pituitary cells. After subcutaneous administration in rats an acute GH secretion was measured, and the best compound, named CJC-1295, produced a 4-fold increase in GH area under the curve over two hours compared with hGRF(1-29). CJC-1295 was described as a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus. It was detectable in plasma beyond 72 hours, and a Western blot showed an immunoreactive species at the position of serum albumin from 15 minutes to beyond 24 hours (Jetté and colleagues, 2005). Mechanistic detail of the chemistry is covered in the DAC versus no-DAC comparison.

2006: the knockout mouse

The next published step was a growth experiment. GHRH-knockout (GHRHKO) mice have isolated GH deficiency and pituitary hypoplasia,. In the 2006 study, 1-week-old GHRHKO mice received CJC-1295 for 5 weeks at intervals of 24, 48 or 72 hours. The mice on the 24-hour interval reached normal body weight and length, those on 48 and 72 hours reached higher body weight and length than placebo without full normalization, and CJC-1295 increased total pituitary RNA and GH mRNA, suggesting somatotroph proliferation (Alba and colleagues, 2006). For research design the useful conclusion is about the relationship between interval and effect: the same amount was less effective as the interval lengthened.

What each step changed for laboratory use

Design stepProblem solvedConsequence at the bench
Truncation to GHRH(1-29)Smaller, cheaper to synthesize, retains activityShort, reproducible solid-phase product
D-Ala2 and related substitutionsResistance to plasma DPP-IV cleavageLonger-lived in plasma or serum-containing media
Position-27 substitutionRemoves an oxidation-prone residueLess sensitivity to oxidation
C-terminal maleimide linker (DAC)Covalent albumin binding, long persistenceReactive group needs handling consideration; assay results depend on albumin content

Why the name has two forms

The "no DAC" label exists because a modified GRF(1-29) without the linker was already in circulation as a research reagent. Once the maleimide form was described, the original-style backbone needed a name that distinguished it, and the two became a standard contrast in GH-axis work: the same peptide chain with and without a mechanism for long persistence. That contrast lets investigators isolate duration as a variable, which is the logic of the CJC-1295 DAC research overview. V8 supplies the CJC-1295 (No DAC) form; the DAC form is not part of the catalog. Product details on that page include a 29-residue sequence, a molecular formula of C152H252N44O42, ≥98% HPLC purity and storage at 2–8 °C with −20 °C for long term.

Reading the primary papers critically

Each paper in this chain answers a narrow question, and it helps to keep the question in mind. The 1982 papers are isolation and sequencing work, so their claims are chemical: the identity of a peptide and its source. The 1986 paper is an enzymology and pharmacokinetics study in plasma, so its half-life values describe the intact 44-residue hormone under those conditions and cannot be carried to a modified analog. The 2005 paper is a bioconjugation and pharmacology study in rats, and its headline 4-fold figure compares area under the curve over two hours against the unmodified fragment, not against any other analog. The 2006 paper is a growth study in a knockout strain with a specific genetic deficiency, so its result concerns that model. When these findings are summarized elsewhere, the most common error is to merge them into a single statement of "extended half-life" that drops the species, the comparator and the time window.

A second habit worth keeping is to separate the molecule from the formulation. A maleimide-bearing peptide that binds albumin in vivo behaves differently in a buffer-only assay, where no albumin is present, than in serum-containing medium. A comparison between DAC and no-DAC forms in cell culture is therefore a comparison that depends on what is in the medium, and that detail must appear in the methods. Related background on measurement is in understanding HPLC purity and how to read a COA.

What the history does not establish

A reader should keep three limits in view. First, the primary papers cited are rodent and cell studies, and conclusions drawn from them are conclusions about those systems. Second, the 2005 and 2006 papers were produced by or with the sponsor that developed the molecule, which is normal for early development but means independent replication matters. Third, later human studies of the molecule exist in the literature, and they are outside the scope of this laboratory-research article; no inference about use outside the laboratory is made here. For related reading see hexarelin and ipamorelin for the separate GH-secretagogue receptor family, and CJC-1295 vs sermorelin for the closest relative of the starting fragment. Browse the catalog for supplied reagents.

For laboratory research use only.

Frequently asked questions

Who first isolated GHRH?

Two groups reported isolating growth-hormone-releasing factor from human pancreatic islet tumors in 1982, in Science (Guillemin and colleagues) and in Nature (Rivier and colleagues).

Why was the N-terminus modified in later analogs?

Plasma dipeptidylaminopeptidase cleaves GHRH at the N-terminus to give a product with less than one-thousandth of the activity (Frohman and colleagues, 1986). Substitutions such as D-Ala2 protect that bond.

What does DAC stand for?

Drug affinity complex, a reactive group that lets the peptide bind covalently to albumin after it enters the bloodstream, extending its persistence.

Where does the maleimide attach?

CJC-1295 was described as a tetrasubstituted hGRF(1-29) with an N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus, designed to bind Cys34 of albumin.

What did the 2005 rat paper report?

The best conjugate, CJC-1295, produced a 4-fold increase in GH area under the curve over two hours versus hGRF(1-29), and was present in plasma beyond 72 hours.

What did the 2006 knockout mouse study show?

Once-daily administration normalized body weight and length in GHRH-knockout mice, and less frequent intervals were less effective, with pituitary RNA and GH mRNA increased.

Why is albumin used as a carrier?

It is abundant and long-lived, partly because the neonatal Fc receptor protects it from degradation, so a peptide bound to it shares that persistence.

What is the difference between CJC-1295 with and without DAC?

Both share the modified GRF(1-29) backbone. Only the DAC form carries the linker that binds albumin.

Does V8 supply the DAC form?

No. The catalog lists the no-DAC form, and this article is background history for laboratory readers.

Does the history say anything beyond laboratory work?

No. The cited studies are rodent and cell work, and this article makes no claims outside the laboratory.

Related reading: CJC-1295 DAC Mechanism of Action and Half-Life, CJC-1295 DAC Pharmacokinetics: Half-Life Explained, CJC-1295 DAC Storage, Stock Math and Study Parameters.

References

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
  2. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
  3. Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985;315(6018):413-416. doi:10.1038/315413a0
  4. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
  5. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  6. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
  7. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315-322. doi:10.1084/jem.20021829
  8. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183. doi:10.1016/j.jconrel.2008.05.010

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.